Skip to content

Clinical trials

Aortic Dissection trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Aortic Dissection Clear all

203 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20023
20041
20062
20071
20083
20092
20103
20114
20126
20137
20149
201511
20167
20177
201810
201914
20209
202116
202220
202318
202413
202514
202618

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed60
Unknown status54
Recruiting38
Not yet recruiting20
Active, not recruiting14
Enrolling by invitation6
Terminated6
Withdrawn4
Approved for marketing1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
W.L.Gore & Associates8
Beijing Anzhen Hospital7
Nanjing Medical University6
Qilu Hospital of Shandong University6
Xijing Hospital6
First Affiliated Hospital Xi'an Jiaotong University5
Hangzhou Endonom Medtech Co., Ltd.5
First Affiliated Hospital of Zhejiang University4
JOTEC GmbH4
Shanghai Zhongshan Hospital4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Aortic Dissection203
Aortic Aneurysm41
Aortic Aneurysm, Thoracic24
Aortic Diseases21
Aneurysm14
Cardiovascular Diseases12
Aortic Aneurysm, Thoracoabdominal8
Heart Valve Diseases8
Vascular Diseases8
Disease7

Trials

Showing 1 to 25 of 203. Each trial links to its page on Pharma Observatory.

103 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.